![conference banner](/images/conference-banner.jpeg)
摘要
背景:肝细胞癌(HCC)是最致命的肝癌。慢性肝炎和随后的肝纤维化和肝硬化是导致肝癌的主要原因。HBV感染不仅导致肝癌,而且导致肝外恶性肿瘤。但是目前对于HBV感染者进行肝细胞癌筛查的重要性及其途径、肝癌的危险因素、导致肝细胞癌的可能机制以及HBV相关肝细胞癌的潜在治疗方法的研究较少。 方法:综述现有研究HBV相关性HCC的筛查、危险性、新的生物标志物、机制及治疗。 结果:血清甲胎蛋白(AFP)应用于慢性乙型肝炎患者的HCC筛查。HBV高载量与肝癌风险增加有关。HBV基因型和基因多态性有助于增加HCC的风险。ku86,ku86抗体,miR-18a,miR-122、miR-150可能是乙肝病毒相关性肝细胞癌的可靠指标。Micro RNAs与HBx在HBV相关的HCC中发挥关键作用。两种类型的药物,传统的干扰素(IFN),核苷类似物(NAS),最近已成为治疗慢性乙型肝炎感染有效的药物,但是这些患者的治疗方案尚未建立。 结论:全面了解HBV感染如何引起肝细胞癌的发生,对于开发更有效的抗病毒治疗和预防肝硬化和肝癌转为晚期有着重要意义。定期筛查HBV感染者是减少这些患者HCC发病率的一个切实有效的方法,应加大力度探索更可靠的HCC早期检测标志物,结合干扰素和NAS及其他治疗方法来更好的预防肝癌复发。
关键词: 乙型肝炎病毒,感染,肝癌,肝纤维化,癌,血清AFP
Current Cancer Drug Targets
Title:Hepatitis B Virus (HBV) Infection and Hepatocellular Carcinoma- New Insights for an Old Topic
Volume: 17 Issue: 6
关键词: 乙型肝炎病毒,感染,肝癌,肝纤维化,癌,血清AFP
摘要: Background: Hepatocellular carcinoma (HCC) is the most deadly form of liver cancer. Chronic hepatitis and subsequent liver fibrosis and cirrhosis are the major causes of HCC. HBV infection results not only in HCC but also extra-hepatic cancers. However, the importance and approaches for HCC screening in HBV infected individuals, the risk factors of HCC, the possible mechanisms leading to HCC and the potential therapeutic approaches of HBV-related HCC have less been systematic reviewed.
Methods: In this study, we reviewed the screening, risk, new biomarker, mechanism and therapeutic of HBV-related HCC. Results: Serum AFP should be used for the HCC screening in CHB patients. Higher HBV viral load is associated with increased risk of HCC. HBV genotype and genetic polymorphism contribute to the risk of HCC.Ku86, Ku86 antibody, miR-18a, miR-122 and miR-150 may be reliable markers of HBVrelated HCC. MicroRNAs and HBx play a key role in HBV-related HCC. Two types of drugs, conventional interferon (IFN), and nucleoside analogs (NAs), have recently become available for the treatment of CHB infection. However, treatment guidelines for these patients have not yet established. Conclusion: A comprehensive understanding of how HBV infection causes HCC is of great importance in developing more effective antiviral therapy and prevention of late stage consequences such as cirrhosis and HCC. Regular screening in HBV infected individuals is a practically useful approach in reducing the HCC incidence in these patients. More reliable markers for HCC early detection should be explored. Combining IFNs and NAs with other curative approaches have superior benefits in preventing HCC recurrence.Export Options
About this article
Cite this article as:
Hepatitis B Virus (HBV) Infection and Hepatocellular Carcinoma- New Insights for an Old Topic, Current Cancer Drug Targets 2017; 17 (6) . https://dx.doi.org/10.2174/1568009616666160926124530
DOI https://dx.doi.org/10.2174/1568009616666160926124530 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
Role of Immune and Genotoxic Response Biomarkers in Tumor Microenvironment in Cancer Diagnosis and Treatment
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process of exploring and investigating the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Understanding XPO1 Target Networks Using Systems Biology and Mathematical Modeling
Current Pharmaceutical Design Synthesis and Evaluation of 99mTc Chelate-conjugated Bevacizumab
Current Radiopharmaceuticals A Systems Pharmacokinetic and Pharmacodynamic Approach to Identify Opportunities and Pitfalls in Energy Stress-Mediated Chemoprevention: The Use of Metformin and Other Biguanides
Current Drug Targets Foreword: The Year in Review: Comments on Plants, Cyclodextrins, Microbiota, and Diabetes
Current Pharmaceutical Design Use of Cell Lines in the Investigation of Pharmacogenetic Loci
Current Pharmaceutical Design Roles of miRNA in the Initiation and Development of Colorectal Carcinoma
Current Pharmaceutical Design Inhibitors of Acyl-Coenzyme A: Cholesterol Acyltransferase
Current Drug Targets - Cardiovascular & Hematological Disorders Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Lung Cancer
Recent Patents on Anti-Cancer Drug Discovery A Combination of Two Antioxidants (An SOD Mimic and Ascorbate) Produces a Pro-Oxidative Effect Forcing Escherichia coli to Adapt Via Induction of oxyR Regulon
Anti-Cancer Agents in Medicinal Chemistry Expression, Distribution and Regulation of Phosphodiesterase 5
Current Pharmaceutical Design Alpha1-Antitrypsin Deficiency: Transition of Care for the Child With AAT Deficiency into Adulthood
Current Pediatric Reviews Alkaloids as Cyclooxygenase Inhibitors in Anticancer Drug Discovery
Current Protein & Peptide Science Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) as a Target for Concurrent Management of Diabetes and Obesity-Related Cancer
Current Pharmaceutical Design Amino Acid Transporter-Targeted Radiotracers for Molecular Imaging in Oncology
Current Medicinal Chemistry Brain Tumor-Related Epilepsy
Current Neuropharmacology Inhibitors of 5α-Reductase in the Treatment of Benign Prostatic Hyperplasia
Current Pharmaceutical Design The Nuclear Orphan Receptor NR4A1 and NR4A3 as Tumor Suppressors in Hematologic Neoplasms
Current Drug Targets Mining the Adenovirus "Virome" for Systemic Oncolytics
Current Pharmaceutical Biotechnology Lectin-Immobilized Fluorescent Nanospheres for Targeting to Colorectal Cancer from a Physicochemical Perspective
Current Drug Discovery Technologies